CDK4/6 and aromatase inhibitors as first‐line treatment in metastatic high‐grade neuroendocrine carcinoma of the breast: A case report

CDK4/6 and aromatase inhibitors as first‐line treatment in metastatic high‐grade neuroendocrine carcinoma of the breast: A case report

Key Clinical Message There is no consensus regarding the therapeutic approach of breast neuroendocrine carcinomas (NECs). As most NECs are hormone receptor positive and HER‐2 negative, we suggest that endocrine‐based strategies may play a leading role. Here, we report a new treatment strategy by inc...

Full description

Bibliographic Details
Main Authors: Dionysia N. Zouki, Vasiliki‐Elpida Kardara, Stephanie Ioannou, Eleni Arvanitou, Konstantinos Exarchos, Konstantinos Gkikas, Stefanos Konstantoudakis, Sophocles Lanitis, Stylianos Benakis, Dimitrios Tryfonopoulos
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Clinical Case Reports
Subjects:
breast neuroendocrine carcinoma
CDK4/6 inhibitors
hormonal therapy
treatment strategy
Online Access:https://doi.org/10.1002/ccr3.9180

Internet

https://doi.org/10.1002/ccr3.9180

Similar Items